Stockreport

Novo Nordisk Eyes Rare Disease Growth As Etavopivat Phase 3 Succeeds [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF Novo Nordisk (CPSE:NOVO B) reported that its phase 3 HIBISCUS trial of etavopivat for sickle cell disease met both co primary endpoints. The investigational therapy r [Read more]